A Single-Arm Study Evaluating the Efficacy of Liquid Acupuncture Therapeutics in Chronic Hepatitis B (CHB)

December 29, 2008 updated by: Yu Medical Garden

Efficacy Study of Liquid Acupuncture(Herb Acupoint Injection) Therapeutics in Chronic Hepatitis B(CHB) Based on Patients' Individual Condition

Study Purpose:

The purpose of this study is to assess that Liquid Acupuncture(Herb Acupoints Injection) Therapeutics could achieve permanent efficacy response in Chronic Hepatitis B.

Efficacy Assessment:

At cessation of the Treatment(about at 24 weeks)comparing Testing Data with the Normal Criteria and their individual baseline.Continue for monitoring the Status 1-5 years.

Data Analysis:

Each 4 weeks collecting Patients' testing data and fill a table.A summary table will be presented as frequency tables for categorical variables as number or percentage.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Inclusion Criteria & Outcome:

Documented chronic hepatitis B infection positive serum HBV-DNA 10^5 copies/mL & above.

Permanent efficacy response after whole treatment circle close(about 24 weeks,someone may be later than 24 weeks but within 48 weeks)

  • HBeAg loss(if HBeAg positive)
  • Liver Function normal(if Liver Function off normal)
  • HBV DNA non-detectability (PCR <500 copies/ml)
  • Image of chronic diffuse hepatic disease will recover up to normal if have.
  • HBsAg titer will decrease continually up to loss after cessation of the treatment.

Treatment Procedure:

Patients will be involved in the study for up to 24-48 weeks from enrollment. There is no external sponsor, commercial sponsor nor governmental agency on this study. The study will be conducted only by Dr. Yu, Ke Heng,who is master of the Liquid Acupuncture(Herb Acupoint Injection)practice more than 30 years.About 30 subjects will be involved in the study overall. All the subjects can be filled up worldwide.

Patients will be required to rent apartment or house for staying at the city(Xiamen city,China preferred).Dr. Yu will go to the Patients' site for treatment practice weekly,each 4 weeks is one circle(the first 3 weeks for treatment practice and last week for Test collection).Appointed Hospitals for test must be certificated and qualified(Chang Gang Hospital preferred).Dr. Yu will explain the test results individually.

Study Type

Interventional

Enrollment (Anticipated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female subjects aged 18-55 years inclusive.
  • Documented chronic hepatitis B infection determined by the presence of serum HBsAg for at least 6 months.
  • Serum HBV DNA ≥ 10^4 copies/mL(PRC).
  • Use of interferon alfa, thymosin, or antiviral agents less than 1 year and not receive them more than 2 months. (If you expect to stop these agents but worry about the risk, you may ask us to help.)
  • Agree not to participate in any other investigational trials or to undertake other HBV systemic antiviral regimens during participation in this study.
  • Able to give written informed consent and comply with the requirements of the study.

Exclusion Criteria:

  • Superinfection/Coinfection with hepatitis A, hepatitis C, hepatitis D, hepatitis E or HIV.
  • Autoimmune hepatitis (antinuclear antibody titre > 1:160).
  • Use of interferon alfa, thymosin, or antiviral agents more than 1 year.
  • Pregnant or nursing.
  • Any serious or active medical or psychiatric illnesses other than hepatitis B which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol. This would include, may not limit to, renal, cardiac, pulmonary, vascular, neurogenic, digestive, metabolic (diabetes, thyroid disorders, adrenal disease), immunodeficiency disorders, active infection or cancer.
  • Clinical signs of decompensated liver disease at baseline. These may include but are not limited to:serum bilirubin > 2.5 mg/dL (≤ 43 µmol/L), prothrombin time > 2 second prolonged above ULN,serum albumin < 35g/L,history of ascites, variceal bleeding, or encephalopathy,Alanine aminotransferase (ALT) >10 times ULN at screening or history of acute exacerbation leading to transient decompensation.

  • Hepatocellular carcinoma as evidenced by one of the following:

    • suspicious foci on ultrasound or radiological examination.
    • where no positive ultrasound finding, but serum alpha-fetoprotein > 100ng/mL
    • Active alcohol or drug abuse or history of alcohol or drug abuse considered by the investigator to be sufficient to hinder compliance with treatment, participation in the study or interpretation of results.
  • Received hepatotoxic drugs (e.g., anabolic steroids, ketaconazole, itraconazole, isoniazid, rifampin, rifabutin) within 2 months prior to study screening or expected to receive these during the course of the study.
  • Received nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, vancomycin, cidofovir, foscarnet, cis-platinum, pentamidine etc.) or competitors of renal excretion (e.g., probenecid) within 2 months prior to study screening or the expectation that patient will receive any of these during the course of the study.
  • Receiving systemic (intravenous or oral) steroids, immuno-suppressant therapies or chemotherapeutic agents within 2 months of study screening or expected to receive these agents during the course of the study.
  • Neutrophile granulocyte count <1.0*10e9/L and Platelet count < 30*10e9/L.
  • Inability to comply with study requirements.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Antiviral Therapy
Liquid Acupuncture(Herb Acupoints Injection) Therapeutics was researched and developed by Herbalist Yu Ru Lin in early of 1950s and used by Yu Medical Garden till now. It is an integrated therapeutics,according to individual condition, select the Acupoints(not limit to current used common acupoints) and proper herbs made individually.It is a special medical treatment conception, which theory is utilizing patients' condition, mobilizing their individual internal curability,therefore the final efficacy can be retrieved.
Device: Liquid Acupuncture (Herb Acupoint Injection)
Each 4 weeks per one circle.The first 3 weeks for treatment practice(one per week)and the last week for test collection.
Other Names:
  • Antiviral Agents

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Permanent Efficacy response after whole treatment circle close(about 24-48 weeks): 1、HBeAg loss(if HBeAg positive) 2、HBV DNA non-detectability (PCR <500 copies/ml) 3、Liver function normal(If Liver function off normal)
Time Frame: 1-2 years
1-2 years

Secondary Outcome Measures

Outcome Measure
Time Frame
HBsAg titer will decrease continually up to loss after cessation of the treatment.
Time Frame: one year later
one year later

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yu Medical Garden

Investigators

  • Principal Investigator: Ke Heng Yu, Yu Medical Garden

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2009

Primary Completion (Anticipated)

September 1, 2009

Study Completion (Anticipated)

March 1, 2010

Study Registration Dates

First Submitted

December 29, 2008

First Submitted That Met QC Criteria

December 29, 2008

First Posted (Estimate)

December 30, 2008

Study Record Updates

Last Update Posted (Estimate)

December 30, 2008

Last Update Submitted That Met QC Criteria

December 29, 2008

Last Verified

December 1, 2008

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • YMG-PR-001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Liver Diseases

Clinical Trials on Liquid Acupuncture (Herb Acupoint Injection)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe